Pliant Therapeutics (NASDAQ: PLRX)
Pliant Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Pliant Therapeutics Company Info
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
News & Analysis
Why Shares of Pliant Therapeutics Are Rising Tuesday
The company's lead therapy fared well in a phase 2a trial to treat two separate conditions.
Why Pliant Therapeutics Stock Is Skyrocketing This Week
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Could Pliant Therapeutics Stock Double Your Money?
Wall Street thinks this red-hot biotech stock has a lot more room to run.
Why Pliant Therapeutics Stock Is Crushing It Today
A positive mid-stage trial readout in idiopathic pulmonary fibrosis is powering the biotech's stock higher.
Why Pliant Therapeutics Stock Is Surging Today
A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.
Could This Recent IPO Biotech Become the Next Moderna?
There's a chance that it could become an even bigger success story.
Pliant Therapeutics Up 33% on IPO Pricing
Investors are excited about the biotech's prospects, but the company still has a long road ahead.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.